79201-18-6

Upstream product

• 79201-17-5 2,2-dimethyl-3-(p-toluenesulfonamido)-1-propanol p-toluenesulfonate 
• 19816-92-3 3,3-dimethyl azetidine 
• 98-59-9 p-toluenesulfonyl chloride 
• 70-55-3 toluene-4-sulfonamide 
• 1619-62-1 2,2-dimethylmalonic acid diethyl ester 
• 126-30-7 2,2-Dimethyl-1,3-propanediol 
• 53555-41-2 2,2-dimethylpropane-1,3-diyl dimethanesulfonate 
• 26734-09-8 3-amino-2,2-dimethylpropan-1-ol 
• 1572-98-1 2-cyano-2-methyl-propionic acid ethyl ester 
• 157736-55-5 2,2-dimethyl-<<4-methylphenylsulfonyl>oxy>propanenitrile 
• 19295-57-9 3-hydroxy-2,2-dimethylpropionitrile 

Downstream Products

• 89381-03-3 3,3-dimethylazetidine hydrochloride 
• 1426414-80-3 2-(3,3-dimethyl-1-azetidinylmethyl)phenylboronic acid 
• 13509-71-2 3,3-dimethyl-1-(phenylmethyl)azetidine 
• 19816-92-3 3,3-dimethyl azetidine 

Relevant academic research and scientific papers

Site-Specific Alkene Hydromethylation via Protonolysis of Titanacyclobutanes

Methyl groups are ubiquitous in biologically active molecules. Thus, new tactics to introduce this alkyl fragment into polyfunctional structures are of significant interest. With this goal in mind, a direct method for the Markovnikov hydromethylation of alkenes is reported. This method exploits the degenerate metathesis reaction between the titanium methylidene unveiled from Cp2Ti(μ-Cl)(μ-CH2)AlMe2 (Tebbe's reagent) and unactivated alkenes. Protonolysis of the resulting titanacyclobutanes in situ effects hydromethylation in a chemo-, regio-, and site-selective manner. The broad utility of this method is demonstrated across a series of mono- and di-substituted alkenes containing pendant alcohols, ethers, amides, carbamates, and basic amines.

9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUND

The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, R9a, R9b, R10, R11, R12, R13a and R13b are each independently as defined in the description.

9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS

The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, R9a, R9b, R10, R11, R12, R13a and R13b are each independently as defined in the description.

Novel acetylcholine and carbamoylcholine analogues: Development of a functionally selective α4β2 nicotinic acetylcholine receptor agonist

A series of carbamoylcholine and acetylcholine analogues were synthesized and characterized pharmacologically at neuronal nicotinic acetylcholine receptors (nAChRs). Several of the compounds displayed low nanomolar binding affinities to the α4β2 nAChR and pronounced selectivity for this subtype over α3β4, α4β4, and α7 nAChRs. The high nAChR activity of carbamoylcholine analogue 5d was found to reside in its R-enantiomer, a characteristic most likely true for all other compounds in the series. Interestingly, the pronounced α4β2 selectivities exhibited by some of the compounds in the binding assays translated into functional selectivity. Compound 5a was a fairly potent partial α4β2 nAChR agonist with negligible activities at the α3β4 and α7 subtypes, thus being one of the few truly functionally selective α4β 2 nAChR agonists published to date. Ligand-protein docking experiments using homology models of the amino-terminal domains of α4β2 and α3β4 nAChRs identified residues Val111(β2)/Ile113(β4) , Phe119(β2)/Gln121(β4), and Thr155(α4)/Ser150(α3) as possible key determinants of the α4β2/α 3β4-selectivity displayed by the analogues.

A NOVEL SYNTHESIS OF 3,3-(SPIRO)SUBSTITUTED AZETIDINES

A smooth and efficient new synthesis for 3,3-disubstituted azetidines, starting from readily available nitriles, was estabilished: α-hydroxymethylation of the starting materials, followed by O-tosylation and LiAlH4-reduction of the key intermediates thus obtained, led - via spontaneous cyclization of the intermediate amino derivatives - to 3,3-disubstituted azetidines.Scope and limitations of this new method were studied with respect to generalized applicability: the target compounds were accessible in good yields for a variety of starting materials (cyclic and acyclic di(hetero)aryl, (hetero)arylalkyl, dialkyl, as well as basic moieties).The products thus obtained may be of interest for ensuing conversions due to their unblocked nitrogen.

Enamines of 3,3-Dimethylazetidine

In an improvement over previous procedures, 3,3-dimethylazetidine (3) has been synthesized in 26percent yield from ethyl cyanoacetate.Rates of formation for the enamines of 3 and of pyrrolidine with 2-methylcyclohexanone (1) and 1-tetralone (2) have been studied.The 5- to 10-fold rate increase observed for 3 is attributed to diminished steric hindrance relative to pyrrolidine.Compared to the enamines of pyrrolidine with 1 and 2, those of 3 methylate initially on nitrogen to ggreater degree and are less selective for monomethylation.The enamine formed between 1 and 3 exists at equilibrium as an 83.17 mixture of tri- and tetrasubstituted isomers, in which the less substituted isomer has its vinyl H 1H NMR peak at δ 4.10.These properties are compared to those of other enamines of 1, in which a predictive relationship had previously been suggested.